首页 | 本学科首页   官方微博 | 高级检索  
     


Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia
Affiliation:1. Centro Hospitalar Universitário de Lisboa Norte, Lisbon, Portugal;2. Sociedade Portuguesa de Pneumologia (SPP), Lisbon, Portugal;3. Associação Portuguesa de Medicina Geral e Familiar (APMGF), Lisbon, Portugal;4. Sanofi Pasteur, Lisbon, Portugal
Abstract:In 2015, inactivated quadrivalent influenza vaccine (QIV) was first introduced into the Australian market. A routine vaccine safety surveillance system in Western Australia was used to conduct post-licensure surveillance of adverse events following immunization with inactivated QIV and trivalent influenza vaccines (TIV) in a sample of 1685 healthcare providers (HCPs). A similar percentage of HCPs who received QIV reported having any reaction seven days post-vaccination as HCPs who received TIV (13.6 vs. 12.8%, respectively; p = 0.66). However, a slightly higher percentage of HCPs who received QIV reported pain or swelling at the injection site as compared to HCPs who received TIV (6.9% vs. 4.2%, respectively; p = 0.02). No serious vaccine-associated adverse events were detected during follow-up of either vaccine. Acknowledging the study limitations, the results of this post-marketing surveillance support the safety of QIV, suggesting there is little difference in the reactogenicity of QIV as compared to TIV.
Keywords:Vaccination  Public health surveillance  Inactivated quadrivalent influenza vaccine  Influenza vaccine  Vaccine safety
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号